164 related articles for article (PubMed ID: 37448573)
21. Integrating virtual screening, pharmacoinformatics profiling, and molecular dynamics: identification of promising inhibitors targeting 3CLpro of SARS-CoV-2.
Mohammad A; Zheoat A; Oraibi A; Manaithiya A; S Almaary K; Allah Nafidi H; Bourhia M; Kilani-Jaziri S; A Bin Jardan Y
Front Mol Biosci; 2023; 10():1306179. PubMed ID: 38516396
[No Abstract] [Full Text] [Related]
22. Molecular Docking of Azithromycin, Ritonavir, Lopinavir, Oseltamivir, Ivermectin and Heparin Interacting with Coronavirus Disease 2019 Main and Severe Acute Respiratory Syndrome Coronavirus-2 3C-Like Proteases.
Arouche TDS; Martins AY; Ramalho TC; Júnior RNC; Costa FLP; Filho TSA; Neto AMJC
J Nanosci Nanotechnol; 2021 Apr; 21(4):2075-2089. PubMed ID: 33500022
[TBL] [Abstract][Full Text] [Related]
23. In silico identification of potential inhibitors of key SARS-CoV-2 3CL hydrolase (Mpro) via molecular docking, MMGBSA predictive binding energy calculations, and molecular dynamics simulation.
Choudhary MI; Shaikh M; Tul-Wahab A; Ur-Rahman A
PLoS One; 2020; 15(7):e0235030. PubMed ID: 32706783
[TBL] [Abstract][Full Text] [Related]
24. Design of novel viral attachment inhibitors of the spike glycoprotein (S) of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) through virtual screening and dynamics.
Oany AR; Mia M; Pervin T; Junaid M; Hosen SMZ; Moni MA
Int J Antimicrob Agents; 2020 Dec; 56(6):106177. PubMed ID: 32987103
[TBL] [Abstract][Full Text] [Related]
25.
Sharma A; Goyal S; Yadav AK; Kumar P; Gupta L
J Biomol Struct Dyn; 2022 Jan; 40(1):86-100. PubMed ID: 32896226
[TBL] [Abstract][Full Text] [Related]
26. Identification of novel inhibitors for SARS-CoV-2 as therapeutic options using machine learning-based virtual screening, molecular docking and MD simulation.
Samad A; Ajmal A; Mahmood A; Khurshid B; Li P; Jan SM; Rehman AU; He P; Abdalla AN; Umair M; Hu J; Wadood A
Front Mol Biosci; 2023; 10():1060076. PubMed ID: 36959979
[TBL] [Abstract][Full Text] [Related]
27. Computational investigation of drug bank compounds against 3C-like protease (3CL
Joshi T; Sharma P; Mathpal S; Joshi T; Maiti P; Nand M; Pande V; Chandra S
Mol Divers; 2022 Aug; 26(4):2243-2256. PubMed ID: 34637068
[TBL] [Abstract][Full Text] [Related]
28. Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach.
Molavi Z; Razi S; Mirmotalebisohi SA; Adibi A; Sameni M; Karami F; Niazi V; Niknam Z; Aliashrafi M; Taheri M; Ghafouri-Fard S; Jeibouei S; Mahdian S; Zali H; Ranjbar MM; Yazdani M
Biomed Pharmacother; 2021 Jun; 138():111544. PubMed ID: 34311539
[TBL] [Abstract][Full Text] [Related]
29. Identification of Darunavir Derivatives for Inhibition of SARS-CoV-2 3CL
Ma L; Xie Y; Zhu M; Yi D; Zhao J; Guo S; Zhang Y; Wang J; Li Q; Wang Y; Cen S
Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555652
[TBL] [Abstract][Full Text] [Related]
30. Identifying the natural compound Catechin from tropical mangrove plants as a potential lead candidate against 3CL
Jha RK; Khan RJ; Parthiban A; Singh E; Jain M; Amera GM; Singh RP; Ramachandran P; Ramachandran R; Sachithanandam V; Muthukumaran J; Singh AK
J Biomol Struct Dyn; 2022; 40(24):13392-13411. PubMed ID: 34644249
[TBL] [Abstract][Full Text] [Related]
31.
Maulana S; Wahyuni TS; Widiyanti P; Zubair MS
J Public Health Afr; 2023 Mar; 14(Suppl 1):2508. PubMed ID: 37492544
[TBL] [Abstract][Full Text] [Related]
32. Isatin-based virtual high throughput screening, molecular docking, DFT, QM/MM, MD and MM-PBSA study of novel inhibitors of SARS-CoV-2 main protease.
Varadharajan V; Arumugam GS; Shanmugam S
J Biomol Struct Dyn; 2022 Oct; 40(17):7852-7867. PubMed ID: 33764269
[TBL] [Abstract][Full Text] [Related]
33. Caffeine and caffeine-containing pharmaceuticals as promising inhibitors for 3-chymotrypsin-like protease of SARS-CoV-2.
Elzupir AO
J Biomol Struct Dyn; 2022 Mar; 40(5):2113-2120. PubMed ID: 33094705
[TBL] [Abstract][Full Text] [Related]
34. Novel inhibitors of the main protease enzyme of SARS-CoV-2 identified via molecular dynamics simulation-guided in vitro assay.
Loschwitz J; Jäckering A; Keutmann M; Olagunju M; Eberle RJ; Coronado MA; Olubiyi OO; Strodel B
Bioorg Chem; 2021 Jun; 111():104862. PubMed ID: 33862474
[TBL] [Abstract][Full Text] [Related]
35. Discovery of Natural Bisbenzylisoquinoline Analogs from the Library of Thai Traditional Plants as SARS-CoV-2 3CL
Khamto N; Utama K; Tateing S; Sangthong P; Rithchumpon P; Cheechana N; Saiai A; Semakul N; Punyodom W; Meepowpan P
J Chem Inf Model; 2023 Apr; 63(7):2104-2121. PubMed ID: 36647612
[TBL] [Abstract][Full Text] [Related]
36. SARS-CoV-2 proteases Mpro and PLpro: Design of inhibitors with predicted high potency and low mammalian toxicity using artificial neural networks, ligand-protein docking, molecular dynamics simulations, and ADMET calculations.
Tumskiy RS; Tumskaia AV; Klochkova IN; Richardson RJ
Comput Biol Med; 2023 Feb; 153():106449. PubMed ID: 36586228
[TBL] [Abstract][Full Text] [Related]
37. Study on the mechanism of active components of Liupao tea on 3CL
Ni WJ; Chen XX; Wei SY; Lan LL; Qiu RJ; Ling YP; Zhou DS; Wu ZM; Cao ZH; Yu CP; Zeng Y
J Food Biochem; 2021 May; 45(5):e13707. PubMed ID: 33760271
[TBL] [Abstract][Full Text] [Related]
38. Proposing a fungal metabolite-flaviolin as a potential inhibitor of 3CL
Rao P; Shukla A; Parmar P; Rawal RM; Patel BV; Saraf M; Goswami D
J Biomol Struct Dyn; 2022 Jan; 40(1):348-360. PubMed ID: 32875950
[TBL] [Abstract][Full Text] [Related]
39. Structure-based virtual screening suggests inhibitors of 3-Chymotrypsin-Like Protease of SARS-CoV-2 from Vernonia amygdalina and Occinum gratissimum.
Gyebi GA; Elfiky AA; Ogunyemi OM; Ibrahim IM; Adegunloye AP; Adebayo JO; Olaiya CO; Ocheje JO; Fabusiwa MM
Comput Biol Med; 2021 Sep; 136():104671. PubMed ID: 34332348
[TBL] [Abstract][Full Text] [Related]
40. Development of a Fluorescence-Based, High-Throughput SARS-CoV-2 3CL
Froggatt HM; Heaton BE; Heaton NS
J Virol; 2020 Oct; 94(22):. PubMed ID: 32843534
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]